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Abstract: Plantar heel pain is a common cause of foot pain that affects patients’ quality of life
and represents a significant cost for the healthcare system. Dry needling and percutaneous needle
electrolysis are two minimally invasive treatments that were shown to be effective for the management
of plantar heel pain. The aim of our study was to compare these two treatments in terms of health
and economic consequences based on the results of a published randomized controlled trial. For this,
we evaluated the costs from the point of view of the hospital and we carried out a cost-effectiveness
study using quality of life as the main variable according to the Eq-5D-5L questionnaire. The cost
of the complete treatment with dry needling (DN) was €178.86, while the percutaneous needle
electrolysis (PNE) was €200.90. The quality of life of patients improved and was translated into
+0.615 quality-adjusted life years (QALYs) for DN and +0.669 for PNE. PNE presented an average
incremental cost-effectiveness ratio (ICER) of €411.34/QALY against DN. These results indicate that
PNE had a better cost-effectiveness ratio for the treatment of plantar heel pain than DN.
Keywords: dry needling; percutaneous needle electrolysis; cost-effectiveness analysis; plantar heel
pain; quality of life
1. Introduction
Plantar heel pain (PHP) is a common cause of foot pain and discomfort that affects the
quality of life (QoL) of patients. The frequency and incidence of PHP is uncertain; however,
it is estimated that over the course of a lifetime, 10% of the population might suffer from
this condition [1,2]. PHP places a relatively large burden on public health, being a fairly
common cause of outpatient visits [3] and medical expenses, with cost of PHP treatment
estimated to be between $192 and $376 million in the United States [4].
Clinical practice guidelines recommend the use of conservative treatment for PHP
management, such as joint and soft tissue mobilization or self-stretching home pro-
grammes [5]. In particular, self- stretching home programmes were shown to be effective
for addressing PHP [6]. Furthermore, recent randomised clinical trials (RCTs) showed
that there is an additional effect of reduction of pain severity when self- stretching home
programmes are combined with manual therapy [7]. It was also shown that dry needling
(DN) is effective for managing PHP, although the magnitude of the treatment effect should
be considered against the frequency of minor transitory adverse events [8].
DN and percutaneous needle electrolysis (PNE) are two minimally invasive treatment
modalities that were shown to be effective for PHP management, reducing the mean and
maximum pain since the first treatment session, with long lasting effects [9]. Despite the
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increased use of these treatment modalities in recent years in clinical practice, to the best of
our knowledge, no previous study investigated the cost-effectiveness of PNE and DN on
PHP. Moreover, in the case of PHP, we only found a study analysing the cost-effectiveness
of other interventions, such as the use of foot orthosis [10].
Therefore, the aim of this study was to compare the cost-effectiveness of two alterna-
tive interventions, DN and PNE, in terms of health and economic consequences.
2. Materials and Methods
2.1. Study Design
The primary study was a randomised controlled trial carried out during 2018 and
2019, to compare the effectiveness of two needling interventions, conducted at the Physical
Medicine and Rehabilitation Hospital in Kuwait. The study was conducted in compliance
with the Helsinki Declaration of Human Rights and ethical approval was obtained from
the Medical Ethics Committee of the State of Kuwait Ministry of Health, with reference
number 642/2017 and registration at Clinicaltrials.com, number NCT03236779, available at
https://pubmed.ncbi.nlm.nih.gov/30683124/ (accessed on 15 December 2020).
This secondary study used the effectiveness data obtained in the RCT to perform a
cost-effectiveness study.
2.2. Participants
Participants were included in the randomised controlled trial if they fulfilled the fol-
lowing criteria. (1) Diagnosed with PHP in accordance with the Clinical Guidelines linked
to the International Classification of Function, Disability and Health from the Orthopaedic
Section of the American Physical Therapy Association. (2) Aged 21 to 60 years at admission
to the study, according to the Kuwaiti Ethical Committee. (3) A history of PHP for over one
month, showing no improvements with previous conservative treatment. (4) The ability to
walk 50 m without any support. (5) The presence of myofascial trigger points on plantar
and calf muscles based on an initial physical examination carried out by a physiotherapist
with experience and training in myofascial trigger points. (6) Accepting treatment from a
male physiotherapist. (7) The ability to understand the study and give informed consent,
as well as having signed the consent form. The exclusion criteria were—(1) needle phobia;
(2) needle allergy or hypersensitivity to metals; (3) the presence of coagulopathy or use of
anticoagulants according to medical criteria; (4) the presence of peripheral arterial vascular
disease; (5) pregnancy; (6) dermatological disease affecting the dry needling area; (7) the
presence of any chronic medical condition that might preclude participation in the study,
such as malignancy, systemic inflammatory disorders (e.g., rheumatoid arthritis, psoriatic
arthritis, ankylosing spondylitis, septic arthritis), neurological diseases, polyneuropathy,
mononeuropathy, and sciatica; (8) treatment of PHP with needling or acupuncture during
the last four weeks; (9) history of injection therapy in the heel over the previous three
months; and (10) previous history of foot surgery or fracture.
2.3. Intervention Conditions
The intervention conditions were established during the RCT. All participants signed
the informed consent and were randomised to the DN or PNE group in blocks of 10 patients.
Allocation was randomly assigned using a computer program (Randomizer, https://
www.randomizer.org/ (accessed on 14 January 2018)) with random patient file number
sequences generated by a third person not involved in the study. Each participant received
four individual physical therapy sessions consisting of DN or PNE, once a week, using
specific DN needles (Agu-punt, Barcelona, Spain) [9]. The duration of each session was
approximately 30 min. DN and PNE interventions were performed exactly in the same
way, with the only difference being that the needle was connected to the PNE equipment
during the PNE procedure (“Physio Invasiva” equipment PRIM S.A. Madrid, Spain) to
add a galvanic current to the mechanical effect of the needle. During the first session,
all patients were instructed in a self-stretching protocol [7] that was performed twice a
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day. An independent blinded assessor conducted all assessments at baseline, 4, 8, 12,
26, and 52 weeks of follow-up. Quality of life (QoL) data were used to perform the
cost-effectiveness analysis.
2.4. Costs
The economic evaluation was made retrospectively and from a hospital perspective.
From this, direct healthcare costs were calculated, such as the material used to perform
the needling (sterile gauze, disinfectant, needles), PNE equipment, and the cost of the
physiotherapy and physiatrist sessions. To assess the cost of PNE equipment, two scenarios
were calculated. In one scenario, the total cost of the equipment was included in the cost
of the study, calculating the total number of sessions that were carried out in our study
and the total cost of the equipment was divided by the number of sessions. In the second
scenario, the average number of uses that the equipment can have in a standard clinic per
year and the amortization of the cost of the equipment in a short period of three years
was calculated.
The cost of the physiatrist and the physical therapy was obtained from the bulletin
“Cost analysis and performance evaluation for government health services of the Kuwait
Ministry of Health” (Financial affairs, Budget and Control Department—Cost Accounting
Section) [11]. Costs of usual care were not considered for comparison as the participants
selected were enrolled on the basis that the standard treatment for PHP was not effective
(see inclusion criteria).
2.5. Outcomes
EQ-5D-5L was completed at baseline, 4, 8, 12, 26, and 52 weeks for each patient. This
questionnaire included five dimensions—mobility, self-care, usual activities, pain/discomfort
and anxiety/depression, with five levels of severity, which made it even more robust than
previous versions [12]. To obtain the quality-of-life value based on the EQ-5D questionnaire
data, the ‘EQ-5D-5L Index Value Crosswalk’ tool was used with English preference weights.
Using the study timing, it was possible to obtain the quality-adjusted life years (QALYs), which
was the preferred measure of health outcomes for use in technology appraisals. QALYs were
estimated for each subject using area under the curve analysis.
2.6. Statistical Analysis
The statistical analysis was performed using IBM SPSS Statistics (V.25, IBM, Madrid,
Spain) by intention to treat, with the last observation carried forward. The distribution of
the data was verified by the Kolmogorov-Smirnov normality test and a factorial ANOVA
(Bonferroni test) was performed to evaluate the differences.
To analyze the uncertainty of QALY and costs, a probabilistic analysis was performed
by varying both parameters according to certain ranges of their distribution variable—
QALY and cost pairs were bootstrapped 1000 times to achieve 95% confidence intervals [13].
To summarize, this study considered the proportion of bootstrap replications that fell
below and to the right of the line of the cost-effectiveness threshold. Then, we repre-
sented the incremental cost-effectiveness ratio (ICER) in relation to possible values of the
cost-effectiveness threshold in the cost-effectiveness acceptability curve (CEAC) [14]. To
complete this sensitivity analysis, a univariate analysis of overhead costs was carried out
considering that they could account for up to 30% of the value of direct costs [15].
3. Results
A total of 102 patients with an average age of 48 years were included in the final
economic analysis. Participants were divided in two groups, without significant differences
between groups at baseline (Table 1).
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Gender (male) 15 (29.4%) 15 (29.4%)
Age (years) 49.5 (±8.9) 48.1 (±8.8)
Height, cm 160.5 (8.2) 161.2 (7.9)
Weight, kg 87.5 (16.5) 90.8 (15.2)
Body mass index (kg/m2) 33.9 (±5.5) 35.1 (±6.4)
Duration of symptoms, months 6.0 (6.0) 9.9 (11.5)
Medications, n yes (%)
- Neuromodulators/antiepileptic 18 (35.3) 22 (43.1)
- Painkillers 16 (31.4) 16 (31.4)
- Anti-inflammatory medication 16 (31.4) 17 (33.3)
- Myorelaxant medication 9 (17.6) 8 (15.7)
All values are means (± standard deviation) or number of patients (%).
All results from the original study titled “Comparing two dry needling interventions
for plantar heel pain: a randomised controlled trial” can be found at https://bmjopen.bmj.
com/content/bmjopen/10/8/e038033.full.pdf.
3.1. Costs
The DN and PNE treatment costs evaluated are displayed in Table 2. Costs were not
compared with the usual standard of care costs as one of the inclusion criteria to be enrolled
in the study was “a history of PHP for over one month, showing no improvements with
previous conservative treatment”.
Table 2. Costs.
DN Group Both PNE Group
Sanitary consumables (session) €1.06
PNE equipment - €2300
Cost of PNE per session (204 sessions) €12.21
Cost of PNE per session according to clinic €0.94
Physiatrist (session) €96.03
Physical therapy (session) €43.65
Cost first week of treatment €140.74 €146.26 ± €5.64 *
Total (four sessions) €178.86 €200.90 ± €22.55
* The variations in the cost for the PNE group are due to the calculation with or without amortization of the PNE
equipment.
The cost of sanitary consumables corresponded to the use of gloves, needles, disin-
fectant, and any other material associated with the needling interventions. The cost of the
PNE equipment corresponded to the price of the “Physio Invasiva” equipment (PRIM S.A.
Madrid, Spain), without taxes. With these data, we calculated the cost per session and
asked for feedback from a group of expert physical therapists to closely resemble the real
value of the cost of a session with PNE in the usual clinical scenario.
To complete the costs, it was necessary to add the cost of the personnel who carried
out the treatments and their supervision. These costs are available in the document “Cost
analysis and performance evaluation for government health services 2013–2014” from the
Kuwait Ministry of Health [11]. The cost of the physiatrist and the physical therapy was
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considered to be the same in both groups. Total direct costs of treatment were €22.04 more
expensive in the PNE than in the DN group, because of the use of the specific equipment
for providing the PNE treatment.
3.2. Quality of Life
An improvement in QoL was observed at weeks 4 and 8 in both treatment groups.
However, the PNE group also showed improvements at 52 weeks (Table 3), with significant
differences between groups at 52 weeks (Figure 1).
Table 3. Mean quality of life (QoL) from EQ-5d.












Baseline 0.630 (0.230) - 0.669 (0.215) - 0.039 (0.323)
4th week 0.777 * (0.224) 0.147 0.757 * (0.237) 0.087 −0.020 (0.341)
8th week 0.721 * (0.232) 0.091 0.737 * (0.230) 0.067 0.015 (0.349)
12th week 0.641 (0.298) 0.011 0.694 (0.272) 0.025 0.053 (0.370)
26th week 0.644 (0.287) 0.014 0.722 (0.278) 0.053 0.078 (0.365)
52nd week 0.660 (0.270) 0.034 0.764 * (0.099) 0.099 0.103 ** (0.323)
(± standard deviation); * difference from baseline in means is significant p-value < 0.05; ** difference between groups is significant.
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Figure 1. Variation in quality of life throughout the study. 
Based on the obtained QoL results, treatment with DN presented an improvement of 
+0.615 QALYs while PNE had an improvement of +0.669 (difference of 0.054) QALYs. The 
probability of each alternative being cost effective was reviewed using the bootstrap 
technique as a probability sensitivity analysis. 
The cost-effectiveness ratios of PNE treatment versus DN increased during the study 
period (Table 4). 
Figure 1. Variation in quality of life throughout the study.
Based on the obtained QoL results, treatment with DN presented an improvement
of +0.615 QALYs while PNE had an improvement of +0.669 (difference of 0.054) QALYs.
The probability of each alternative being cost effective was reviewed using the bootstrap
technique as a probability sensitivity analysis.
The cost-effectiveness ratios of PNE treatment versus DN increased during the study
period (Table 4).
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Table 4. Variation of cost-effective ratio during the study.
PNE
Weeks 4 8 12 26 52
% Cost-effective 50% 46% 63% 79% 86%
PNE showed a clear dominance against DN at 52 weeks, presenting even higher costs
for the equipment used (Figure 2)
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Figure 3. Cost-effectiveness acceptability curve (CEAC).
The univariate analysis of estimated overhead costs implied an increased cost of
€60.27 for the PNE group (total €261.17) and €53.66 for the DN group (total €232.52). The
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resulting ICER was €530.55/QALY, 119.25€/QALY more than when overhead costs were
not considered.
4. Discussion
The objective of this study was to analyze which treatment option was more cost-
effective for PHP treatment, on the basis that both DN and PNE were demonstrated to be
effective. For this, we considered that a cost-effectiveness study was the best tool, using
a good efficacy marker such as the patient QoL and evaluating all costs involved at the
health centre. The baseline characteristics of our patient sample were homogeneous, and it
was a good starting point to exclusively assess the variation due to treatment.
We chose the EQ-5D-5l scale mainly because it was one of the most used scales, but
also because it allowed us to make a more global assessment of patient health status.
Comparisons of EQ-5D-5l with other more specific scales such as the Manchester Oxford
Foot Questionnaire (MOXFQ) concluded that both were particularly responsive to changes
in pain, mobility and activity, or social interaction following treatment; but ‘the generic
EQ-5D may allow comparison of general health states in the wider health community’ [16].
However, it has a drawback when it comes to transferring the data from the questionnaire
to QoL, as currently, there is no predefined crosswalk index for Kuwaiti patients. In
communication with EuroQol group experts, it was considered that the most valid option
could be to use the British values.
Our analysis showed an improvement of the QoL in both groups of almost 0.1 point
on the EQ-5D-5l scale. The results obtained by Rome et al. [10] with the use of an ac-
commodative foot orthosis or functional foot orthosis were 0.07 and 0.09 QALY/year,
respectively. If we compare the QALY values gained with DN treatment (0.615) and PNE
(0.669) against these results, we see that there was a considerable improvement with these
needling treatments.
Regarding costs, only those that most influence a clinic, hospital, or a health centre
were considered in terms of equipment and staff. In both cases, the cost of the equipment
was assessed as the consumable material that was used and renewed for each patient and
session. The price of the PNE equipment might have differences depending on the brand
or the country where it was purchased. In this case, we only valued the device used in this
study. To assess the cost of this equipment for each session as accurately as possible, an
average of uses per year and years of amortization was determined. On the other hand, we
also calculated the cost involved for each session in case the equipment was used only for
this study (51 patients, 4 sessions for each one; 204 sessions). The cost with the average of
annual uses and amortization seemed to be the most realistic since this equipment could
be used in many other pathologies.
On the contrary, being among the first to perform cost analyses of this type of tech-
niques might lead to certain limitations, such as the difficulty of assessing the indirect costs.
In this study, we used as a reference the inclusion of indirect costs, represented by a large
weight in the overall evaluation of costs, which might bias the results [17]. The use of
RCT data retrospectively did not allow us to obtain more information of indirect costs and
therefore we did not include them to avoid the distortion of results.
There were improvements in QoL with both treatments, and the differences in costs
between treatments were relatively low. The cost-effectiveness relationships analyzed after
the bootstrapping indicated that there was a clear advantage of PNE over DN at 52 weeks.
These results must be interpreted with caution, taking into account the methodological
limitations of our study, mainly related to the sample size, the lack of studies that served
as a comparison and the high rate of drop-outs. In the latter case, and in the same way as
explained in the published study “either underpowering or the intention to treat analysis
may explain the inconsistency of the results in the PNE group possibly leading to significant
results in weeks 12 and 26” [9], also in cost-effectiveness ratio.
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However, this study also had some strengths, as it is the first study to follow a strict
methodology in the cost-effectiveness analysis of two needling interventions and the data
were extracted from a randomized controlled trial comparing these needling interventions.
This was the first time that a study compared the treatment costs of DN and PNE,
which combined with the cost-effectiveness analysis carried out. This could be helpful for
both administrators and clinicians to assess the inclusion of new treatment methods in
hospitals or rehabilitation clinics.
5. Conclusions
Although both DN and PNE were found to be effective in improving QoL for PHP
management, PNE treatment was more cost-effective than DN, with significant differences
at 52 weeks. In the comparisons made according to the cost-effectiveness analysis, this
translated into an 86% probability that PNE was more cost-effective compared to DN at
52 weeks. Considering the limitations of our study based on the loss of patients from the
previous study and the lack of reliable indirect costs, further studies are needed to verify
the differences in PNE and DN.
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